A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results from an expanded cohort of 500 patients in the ALIGN-AR Pivotal Trial ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

Rising prevalence of cardiovascular diseases and rapid advancements in minimally invasive procedures are fueling the growth of the Heart Valve Devices Market. Valued at US$ 10.9 billion in 2023, the ...